Since intratumoral expression of CXCL8 has been shown to be a negative prognostic marker [31], these observations highlight a potential for targeting the bladder cancer-associated chemokine microenvironments to improve the outcomes of BCG-treatment and chemotherapy of this cancer type. The gene discussed is CXCL8; the disease is urinary bladder cancer.